Although these targeted biologic therapies represent a significant advance in the treatment of CD, there are still some patients who are not sensitive to the targeted drugs (anti-TNF antibodies such as infliximab and adalimumab) that have been identified (Schmitt et al., 2021). Here, TNF is linked to Cowden disease.